Almost At The Phase III Finish Line, Lilly Cuts Arzoxifene Losses
Lilly has decided not to submit the NDA for its osteoporosis drug arzoxifene after Phase III data showed the drug fell short on key secondary outcome measures, the firm announced Aug. 18
You may also be interested in...
Conditions associated with menopause represent a huge market, yet the R&D pipeline has long been slim, despite the well-known drawbacks of marketed hormone replacement therapies. But new approaches with a tissue-selective estrogenic effect are emerging: Shionogi’s Osphena for menopause-related sexual dysfunction broke the long drought in NME approvals, and Pfizer’s broad NDA for bazedoxifene/conjugated estrogens is under review. Emerging companies like EndoCeutics are exploring new hormonal approaches.
As comparative effectiveness research grows in importance, drug manufacturers need to factor it, as well as payer evidence needs, into product development decisions, Novartis Head of Comparative Effectiveness Research and Communications Amy Rudolph says.
Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial